Rohin Mhatre
REPLIGENAbout Rohin Mhatre
Independent director of Repligen Corporation since 2020; age 60. Currently EVP and Chief Technical Officer at Parabilis Medicines (formerly FogPharma) since October 2023; previously Senior Vice President, Product & Technology Development at Biogen (2017–2023) and earlier held multiple bioprocess development leadership roles at Biogen and Applied BioSystems. Ph.D. in Chemistry from Northeastern University; board skills emphasize risk oversight, manufacturing/global operations, and life sciences technology and innovation .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Biogen | Senior Vice President, Product & Technology Development | 2017–2023 | Led product/technology development; earlier six years as VP of Biopharmaceutical Development (cell line, culture, purification, device development) . |
| Biogen | Multiple roles incl. analytical development/technical services | Joined 1996 | Built analytical development and technical services; scaled bioprocess capabilities . |
| Applied BioSystems (formerly Perspective Biosystems) | Led purification and applications group | Not disclosed | Purification/applications leadership prior to Biogen . |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Parabilis Medicines (FogPharma) | EVP & Chief Technical Officer | Since Oct 2023 | Technical operations leadership; manufacturing/process development oversight . |
Board Governance
- Independence: Board determined Dr. Mhatre is independent under Nasdaq standards; all committee members are independent .
- Committees: Member, Compensation Committee (current composition: Barthelemy, Mhatre, Muir, Pax; Chair: Pax effective Feb 2025) .
- Attendance and engagement: Board met 6 times in FY2024; Audit met 6, Compensation met 4, N&CG met 2. The company states every director attended 100% of Board and committee meetings for which they served, except one director who attended 1 of 2 applicable committee meetings; independent director executive sessions held at each Board meeting .
- Lead Independent Director & structure: Separate Executive Chair and Lead Independent Director roles; executive sessions chaired by the Executive Chair or Lead Independent Director .
- Shareholder engagement and ESG oversight: N&CG Chair oversees ESG; compensation-related ESG responsibilities assigned to NEOs annually since 2022 and considered in performance comp (context for committee’s remit) .
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual cash retainer – Board (non-employee directors) | $60,000 | Paid in cash. |
| Lead Independent Director additional retainer | $45,000 | Applies to Lead Independent Director. |
| Committee chair/member retainers – Audit | Chair $30,000; Member $10,000 | Cash. |
| Committee chair/member retainers – Compensation | Chair $20,000; Member $10,000 | Cash. |
| Committee chair/member retainers – N&CG | Chair $16,000; Member $5,000 | Cash. |
| Transaction Committee member | $5,000 | As needed, market-consistent . |
| Director | Fees Earned (Cash) | Total Director Pay (2024) |
|---|---|---|
| Rohin Mhatre | $70,000 | $306,651 |
Performance Compensation
- Annual equity structure (non-employee directors): $240,000 grant-date fair value for directors; 50% RSUs, 50% stock options; annual equity awards vest in full on the earlier of first anniversary or next Annual Meeting; acceleration upon sale event. Chairperson annual equity value $275,000 .
- 2024 awards to Dr. Mhatre:
| Grant Date | RSUs (#) | Options (#) | Option Exercise Price ($) | Grant-Date Fair Value ($) |
|---|---|---|---|---|
| 5/16/2024 | 701 | 1,376 | 171.03 | Stock $119,892; Options $116,759 |
- Vesting: Annual equity awards vest in full on the earlier of the first anniversary of grant or the next Annual Meeting, subject to continued service; sale event acceleration applies to director equity retainers .
Other Directorships & Interlocks
- Current public company boards: None disclosed for Dr. Mhatre (Other Public Boards column shows “–”) .
- Related-party transactions: Company reports no related-party transactions >$120,000 since Jan 1, 2024 (mitigates conflict risk) .
Expertise & Qualifications
- Technical: Deep bioprocess and manufacturing expertise; experience across cell line, purification, device development; chemistry Ph.D. .
- Board skills matrix: Risk oversight; manufacturing/global operations; life sciences technology & innovation .
Equity Ownership
| Holder | Beneficial Ownership (Shares) | % of Class | Breakdown/Notes |
|---|---|---|---|
| Rohin Mhatre | 11,355 | <1% | Includes 9,010 options exercisable within 60 days of Mar 7, 2025 . |
| Unexercised options (as of Dec 31, 2024) | 10,386 | — | Aggregate options outstanding . |
| Unvested RSUs (as of Dec 31, 2024) | 701 | — | Annual director grant unvested at year-end . |
| Shares outstanding (for % calc context) | 56,148,556 | — | Outstanding common shares as of Mar 7, 2025 . |
- Ownership policy: Non-employee directors must hold shares equal to 4x annual cash retainer within 5 years; RSUs count, options/PSUs do not; company states directors/NEOs comply or are on track .
- Hedging/pledging: Prohibited without Audit Committee pre-approval; margin accounts, short sales, derivative hedges restricted per Insider Trading Policy .
Governance Assessment
- Board effectiveness: Dr. Mhatre strengthens technical oversight on the Compensation Committee, which meets four times annually and uses an independent consultant (Meridian) and peer benchmarking to align pay with performance—reinforcing governance rigor .
- Independence and conflicts: Independent director with no disclosed related-party transactions; current industry role at Parabilis/FogPharma presents adjacent sector exposure but no business dealings disclosed with Repligen—low conflict risk signal .
- Alignment: Director equity grants (RSUs/options) and stock ownership guidelines promote alignment; anti-hedging/pledging policy reduces misalignment risk .
- Attendance/engagement: Robust Board/committee cadence and executive sessions of independents each meeting; company discloses near-perfect attendance overall with one director exception not attributed—generally supportive of investor confidence .
- RED FLAGS: None disclosed specific to Dr. Mhatre (no Section 16 delinquency noted; no related-party transactions; no pledging/hedging allowed). Monitor for any future interlocks with customers/suppliers and compliance with ownership guidelines; no current issues flagged .